NCT01046851 is a Phase 3 clinical trial of Nopan in Suicidality, sponsored by Prof. Yoram Yovell.

Who is sponsoring NCT01046851?

NCT01046851 is sponsored by Prof. Yoram Yovell.

What drugs are being tested in NCT01046851?

Interventions in NCT01046851: Nopan, Placebo.

What condition does NCT01046851 study?

NCT01046851 studies Suicidality.

Is NCT01046851 still recruiting?

NCT01046851 is currently status unknown. Last updated 31 December 2011.

Last reviewed 2011-12-31 · How we verify

NCT01046851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3 Study of the Effects of Nopan as add-on Treatment to Antidepressants in Treating Depression and Suicidality

Status unknown Phase 3 Last updated 31 December 2011

What this trial tests

Phase 3 trial testing Nopan in Suicidality in 60 participants. Status unknown.

Timeline

1 September 2008

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Prof. Yoram Yovell
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 September 2008
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	3 locations across Israel

Drugs / interventions tested

Nopan — full drug profile →
Placebo

Conditions studied

Suicidality — all drugs for Suicidality →

Sponsor

Prof. Yoram Yovell

Who can join

Adults 18 to 65, any sex, with Suicidality. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Reduction in Suicidality as expressed by the score on the BSI
Time frame: 4 weeks

Sponsor's own description

Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis.
Riblet NB, Young-Xu Y, Shiner B, Schnurr PP, et al · · 2023 · cited 8× · PMID 37019069 · DOI 10.1016/j.jpsychires.2023.03.037

Verify or expand the search:

Other recruiting trials for Suicidality

Currently open trials in the same condition.

NCT06636357 — Nitrous Oxide in the Treatment of Acute Suicidal Ideation · Phase 2 · recruiting
NCT04197765 — acTBS Treatment for Inpatient Subjects With Suicidality · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01046851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Yoram Yovell
Last refreshed: 31 December 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01046851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing